Mitchell E. Fingerman

Mitchell E. Fingerman, MD, FASA

Specializes In
  • Anesthesiology
Languages Spoken
  • English

Appointments

Sees Patients For

Anesthesiology

Hospital Affiliations

  • Barnes-Jewish Hospital

Locations

Experience

Board Certifications

  • Anesthesiology

Academic Title(s)

Associate Professor, Anesthesiology
Division Chief, Regional & Ambulatory Anesthesiology
Fellowship Director, Regional & Ambulatory Fellowship

Publications & Research

View research profile »

Education

BS

1994 Ithaca College, Ithaca, New York

MS

1995 Ithaca College, Ithaca, New York

Medical Degree

2004 University of Connecticut School of Medicine, Farmington, Connecticut

Residency

2008 Barnes-Jewish Hospital, St. Louis, Missouri

Fellowship

2009 Ambulatory/Regional Anesthesia, Duke University Medical Center, Durham, North Carolina

Financial Disclosures
  • Avanos Medical
    • Speaker Fees: $20,000 - $39,999
    • Reporting Date: 05/01/2023

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.